Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients.

Background: The clinical course of cutaneous melanoma (CM) can differ significantly for patients with identical stages of disease, defined clinico-pathologically, and no molecular markers differentiate patients with such a diverse prognosis. This study aimed to define the prognostic value of whole g...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Translational Medicine Vol. 10; no. 1; pp. 185 - 186
Autores principales: Sigalotti, Luca, Covre, Alessia, Fratta, Elisabetta, Parisi, Giulia, Sonego, Paolo, Colizzi, Francesca, Coral, Sandra, Massarut, Samuele, Kirkwood, John M, Maio, Michele
Formato: research Journal Article
Publicado: BioMed Central 2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104307370&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104307370
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14795876
        1CW3
      jtl: Journal of Translational Medicine
      issn: 14795876
      maglogo: N
    pubinfo:
      dt: 2012
      vid: 10
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        104307370
        NLM22950745
        2011923559
        10.1186/1479-5876-10-185
        NLM22950745
        PMC3539917
        104307370
      ppf: 185
      ppct: 1
      formats:
      tig:
        atl: Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients.
      aug:
        au:
          Sigalotti, Luca
          Covre, Alessia
          Fratta, Elisabetta
          Parisi, Giulia
          Sonego, Paolo
          Colizzi, Francesca
          Coral, Sandra
          Massarut, Samuele
          Kirkwood, John M
          Maio, Michele
      sug:
        subj:
          DNA
          Genome
          Melanoma Metabolism
          Survival Analysis
          Adult
          Aged
          Aged, 80 and Over
          Nucleotides
          DNA Probes
          Female
          Human
          Male
          Melanoma Pathology
          Middle Age
          Polymerase Chain Reaction
          Adult: 19-44 years
          Aged: 65+ years
          Aged, 80 & over
          Middle Aged: 45-64 years
          Female
          Male
      ab: Background: The clinical course of cutaneous melanoma (CM) can differ significantly for patients with identical stages of disease, defined clinico-pathologically, and no molecular markers differentiate patients with such a diverse prognosis. This study aimed to define the prognostic value of whole genome DNA methylation profiles in stage III CM.Methods: Genome-wide methylation profiles were evaluated by the Illumina Human Methylation 27 BeadChip assay in short-term neoplastic cell cultures from 45 stage IIIC CM patients. Unsupervised K-means partitioning clustering was exploited to sort patients into 2 groups based on their methylation profiles. Methylation patterns related to the discovered groups were determined using the nearest shrunken centroid classification algorithm. The impact of genome-wide methylation patterns on overall survival (OS) was assessed using Cox regression and Kaplan-Meier analyses.Results: Unsupervised K-means partitioning by whole genome methylation profiles identified classes with significantly different OS in stage IIIC CM patients. Patients with a "favorable" methylation profile had increased OS (P = 0.001, log-rank = 10.2) by Kaplan-Meier analysis. Median OS of stage IIIC patients with a "favorable" vs. "unfavorable" methylation profile were 31.5 and 10.4 months, respectively. The 5 year OS for stage IIIC patients with a "favorable" methylation profile was 41.2% as compared to 0% for patients with an "unfavorable" methylation profile. Among the variables examined by multivariate Cox regression analysis, classification defined by methylation profile was the only predictor of OS (Hazard Ratio = 2.41, for "unfavorable" methylation profile; 95% Confidence Interval: 1.02-5.70; P = 0.045). A 17 gene methylation signature able to correctly assign prognosis (overall error rate = 0) in stage IIIC patients on the basis of distinct methylation-defined groups was also identified.Conclusions: A discrete whole-genome methylation signature has been identified as molecular marker of prognosis for stage IIIC CM patients. Its use in daily practice is foreseeable, and promises to refine the comprehensive clinical management of stage III CM patients.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N